| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.621 | 0.003 | 0.621 | GABA C receptor agonist | 0.395 0.005 DBMET02215 | ||
| 0.619 | 0.002 | 0.619 | GABA aminotransferase inhibitor | 0.249 0.004 DBMET02215 | ||
| 0.591 | 0.001 | 0.591 | GABA B receptor agonist | 0.133 0.005 DBMET02215 | ||
| 0.588 | 0.014 | 0.588 | Spasmolytic | 0.217 0.107 DBMET02215 | ||
| 0.573 | 0.008 | 0.573 | Anticonvulsant | |||
| 0.562 | 0.024 | 0.569 | Cholesterol antagonist | 0.569 0.023 DBMET02215 | DBMET02215 | |
| 0.532 | 0.002 | 0.532 | GABA B receptor antagonist | 0.044 0.027 DBMET02215 | ||
| 0.488 | 0.005 | 0.488 | Insulin secretagoues | 0.195 0.039 DBMET02215 | ||
| 0.483 | 0.005 | 0.567 | 5 Hydroxytryptamine uptake stimulant | 0.567 0.003 DBMET02215 | DBMET02215 | |
| 0.499 | 0.033 | 0.639 | Aldehyde oxidase inhibitor | 0.639 0.014 DBMET02215 | DBMET02215 | |
| 0.473 | 0.016 | 0.473 | Superoxide dismutase inhibitor | 0.282 0.058 DBMET02215 | ||
| 0.498 | 0.051 | 0.498 | Cyclophilin D inhibitor | |||
| 0.456 | 0.035 | 0.456 | 5 Hydroxytryptamine release stimulant | 0.417 0.042 DBMET02215 | ||
| 0.444 | 0.045 | 0.444 | Toll-Like receptor agonist | 0.38 0.069 DBMET02215 | ||
| 0.409 | 0.015 | 0.409 | Anesthetic general | 0.339 0.026 DBMET02215 | ||
| 0.438 | 0.047 | 0.438 | Toll-Like receptor 7 agonist | 0.386 0.066 DBMET02215 | ||
| 0.431 | 0.042 | 0.431 | Antithrombotic | 0.291 0.094 DBMET02215 | ||
| 0.397 | 0.011 | 0.397 | Phospholipase C inhibitor | 0.234 0.029 DBMET02215 | ||
| 0.39 | 0.005 | 0.39 | Cell adhesion inhibitor | 0.173 0.034 DBMET02215 | ||
| 0.389 | 0.004 | 0.814 | Succinate dehydrogenase inhibitor | 0.814 0.002 DBMET02215 | DBMET02215 | |
| 0.403 | 0.026 | 0.403 | Interleukin 2 agonist | 0.314 0.064 DBMET02215 | ||
| 0.384 | 0.01 | 0.384 | Tyrosine 3 hydroxylase inhibitor | 0.348 0.016 DBMET02215 | ||
| 0.399 | 0.027 | 0.418 | Platelet antagonist | 0.418 0.024 DBMET02215 | DBMET02215 | |
| 0.391 | 0.029 | 0.391 | Hypoglycemic | 0.21 0.104 DBMET02215 | ||
| 0.425 | 0.063 | 0.436 | 5 Hydroxytryptamine release inhibitor | 0.436 0.058 DBMET02215 | DBMET02215 | |
| 0.413 | 0.069 | 0.417 | Histamine release inhibitor | 0.417 0.067 DBMET02215 | DBMET02215 | |
| 0.341 | 0.005 | 0.341 | Cell adhesion molecule inhibitor | 0.093 0.04 DBMET02215 | ||
| 0.345 | 0.008 | 0.345 | Phospholipase A2 inhibitor | 0.181 0.053 DBMET02215 | ||
| 0.397 | 0.064 | 0.397 | Transcription factor NF kappa B inhibitor | 0.295 0.097 DBMET02215 | ||
| 0.336 | 0.005 | 0.459 | Ferrochelatase inhibitor | 0.459 0.003 DBMET02215 | DBMET02215 | |
| 0.39 | 0.066 | 0.551 | GABA C receptor rho-3 antagonist | 0.551 0.014 DBMET02215 | DBMET02215 | |
| 0.308 | 0.006 | 0.441 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.441 0.003 DBMET02215 | DBMET02215 | |
| 0.334 | 0.035 | 0.363 | Psychostimulant | 0.363 0.029 DBMET02215 | DBMET02215 | |
| 0.319 | 0.022 | 0.319 | Gastrin inhibitor | 0.271 0.056 DBMET02215 | ||
| 0.347 | 0.052 | 0.347 | Calcium channel activator | 0.325 0.069 DBMET02215 | ||
| 0.288 | 0.005 | 0.288 | Integrin antagonist | |||
| 0.377 | 0.095 | 0.377 | Analgesic | |||
| 0.333 | 0.051 | 0.333 | Sodium/bile acid cotransporter inhibitor | 0.242 0.137 DBMET02215 | ||
| 0.288 | 0.007 | 0.288 | GABA receptor agonist | |||
| 0.314 | 0.042 | 0.314 | Interleukin agonist | 0.249 0.079 DBMET02215 | ||
| 0.273 | 0.005 | 0.273 | Protein kinase B gamma inhibitor | |||
| 0.312 | 0.052 | 0.312 | Insulysin inhibitor | 0.273 0.077 DBMET02215 | ||
| 0.285 | 0.031 | 0.305 | Non-steroidal antiinflammatory agent | 0.305 0.027 DBMET02215 | DBMET02215 | |
| 0.258 | 0.005 | 0.258 | HIV-1 integrase (Overall Integration) inhibitor | 0.229 0.007 DBMET02215 | ||
| 0.262 | 0.008 | 0.262 | NMDA receptor antagonist | 0.144 0.026 DBMET02215 | ||
| 0.254 | 0.006 | 0.254 | GABA C receptor antagonist | 0.24 0.007 DBMET02215 | ||
| 0.289 | 0.052 | 0.289 | Hypolipemic | |||
| 0.272 | 0.037 | 0.272 | Peptidyltransferase inhibitor | 0.216 0.081 DBMET02215 | ||
| 0.237 | 0.004 | 0.237 | NMDA receptor agonist | 0.192 0.005 DBMET02215 | ||
| 0.232 | 0.009 | 0.281 | Porphobilinogen synthase inhibitor | 0.281 0.006 DBMET02215 | DBMET02215 | |
| 0.255 | 0.042 | 0.255 | Growth hormone agonist | 0.251 0.043 DBMET02215 | ||
| 0.258 | 0.046 | 0.258 | Peroxidase inhibitor | 0.239 0.05 DBMET02215 | ||
| 0.218 | 0.009 | 0.229 | Glutamate dehydrogenase inhibitor | 0.229 0.008 DBMET02215 | DBMET02215 | |
| 0.219 | 0.013 | 0.219 | Cyclooxygenase 3 inhibitor | 0.18 0.027 DBMET02215 | ||
| 0.243 | 0.04 | 0.243 | Anticoagulant | |||
| 0.228 | 0.025 | 0.228 | Neurotensin receptor agonist | 0.181 0.049 DBMET02215 | ||
| 0.24 | 0.04 | 0.254 | Insulin sensitizer | 0.254 0.032 DBMET02215 | DBMET02215 | |
| 0.205 | 0.006 | 0.225 | Phenylalanine 4-hydroxylase inhibitor | 0.225 0.005 DBMET02215 | DBMET02215 | |
| 0.209 | 0.019 | 0.209 | Aminopeptidase B inhibitor | 0.154 0.036 DBMET02215 | ||
| 0.191 | 0.004 | 0.191 | Glycine receptor agonist | 0.138 0.009 DBMET02215 | ||
| 0.206 | 0.023 | 0.263 | Cystathionine beta-synthase inhibitor | 0.263 0.013 DBMET02215 | DBMET02215 | |
| 0.189 | 0.008 | 0.197 | Glutamate decarboxylase inhibitor | 0.197 0.007 DBMET02215 | DBMET02215 | |
| 0.336 | 0.157 | 0.486 | Caspase 9 stimulant | 0.486 0.065 DBMET02215 | DBMET02215 | |
| 0.206 | 0.028 | 0.223 | Arachidonic acid antagonist | 0.223 0.015 DBMET02215 | DBMET02215 | |
| 0.184 | 0.013 | 0.318 | Triose-phosphate isomerase inhibitor | 0.318 0.004 DBMET02215 | DBMET02215 | |
| 0.187 | 0.018 | 0.187 | Catalase inhibitor | 0.181 0.019 DBMET02215 | ||
| 0.202 | 0.033 | 0.341 | Alpha-N-acetylglucosaminidase inhibitor | 0.341 0.012 DBMET02215 | DBMET02215 | |
| 0.199 | 0.033 | 0.199 | Hemostatic | |||
| 0.168 | 0.005 | 0.168 | Neurokinin 2 antagonist | |||
| 0.182 | 0.018 | 0.182 | Interleukin 8 antagonist | 0.116 0.067 DBMET02215 | ||
| 0.185 | 0.022 | 0.192 | Adenylate cyclase stimulant | 0.192 0.018 DBMET02215 | DBMET02215 | |
| 0.172 | 0.013 | 0.265 | Electrolyte absorption antagonist | 0.265 0.004 DBMET02215 | DBMET02215 | |
| 0.165 | 0.007 | 0.165 | Glutamate release inhibitor | 0.123 0.02 DBMET02215 | ||
| 0.164 | 0.008 | 0.166 | Lanosterol 14 alpha demethylase inhibitor | 0.166 0.007 DBMET02215 | DBMET02215 | |
| 0.267 | 0.111 | 0.273 | Apoptosis antagonist | 0.273 0.106 DBMET02215 | DBMET02215 | |
| 0.233 | 0.078 | 0.281 | Angiogenesis stimulant | 0.281 0.057 DBMET02215 | DBMET02215 | |
| 0.167 | 0.017 | 0.167 | Folate antagonist | 0.11 0.049 DBMET02215 | ||
| 0.184 | 0.037 | 0.184 | Cell wall synthesis inhibitor | 0.183 0.038 DBMET02215 | ||
| 0.148 | 0.004 | 0.148 | Integrin beta5 antagonist | |||
| 0.197 | 0.053 | 0.197 | Thrombolytic | 0.168 0.069 DBMET02215 | ||
| 0.167 | 0.023 | 0.167 | Sphingosine 1-phosphate receptor 2 antagonist | 0.162 0.028 DBMET02215 | ||
| 0.146 | 0.003 | 0.146 | Free fatty acid receptor 1 agonist | 0.06 0.004 DBMET02215 | ||
| 0.146 | 0.004 | 0.146 | Glutamate (mGluR3) antagonist | 0.063 0.007 DBMET02215 | ||
| 0.159 | 0.018 | 0.166 | GABA C receptor rho-1 antagonist | 0.166 0.016 DBMET02215 | DBMET02215 | |
| 0.175 | 0.035 | 0.189 | Aldehyde dehydrogenase inhibitor | 0.189 0.031 DBMET02215 | DBMET02215 | |
| 0.15 | 0.01 | 0.15 | CXC chemokine receptor antagonist | |||
| 0.139 | 0.004 | 0.139 | Integrin alphaVbeta3 antagonist | |||
| 0.154 | 0.019 | 0.154 | Histidine decarboxylase inhibitor | 0.104 0.03 DBMET02215 | ||
| 0.259 | 0.126 | 0.259 | Vasodilator, coronary | 0.238 0.146 DBMET02215 | ||
| 0.137 | 0.004 | 0.137 | Vitronectin receptor antagonist | |||
| 0.156 | 0.024 | 0.214 | Adenylate kinase inhibitor | 0.214 0.013 DBMET02215 | DBMET02215 | |
| 0.161 | 0.029 | 0.161 | Vanilloid 1 agonist | 0.161 0.029 DBMET02215 | ||
| 0.22 | 0.088 | 0.22 | Neuropeptide Y2 antagonist | |||
| 0.138 | 0.008 | 0.138 | NMDA 2A receptor antagonist | 0.063 0.028 DBMET02215 | ||
| 0.158 | 0.027 | 0.173 | Ca2+-transporting ATPase inhibitor | 0.173 0.011 DBMET02215 | DBMET02215 | |
| 0.18 | 0.05 | 0.201 | Protein kinase stimulant | 0.201 0.041 DBMET02215 | DBMET02215 | |
| 0.143 | 0.014 | 0.143 | Aminopeptidase I inhibitor | 0.114 0.021 DBMET02215 | ||
| 0.133 | 0.005 | 0.146 | Aconitate hydratase inhibitor | 0.146 0.004 DBMET02215 | DBMET02215 | |
| 0.205 | 0.081 | 0.205 | Nitric-oxide synthase stimulant | 0.201 0.088 DBMET02215 | ||
| 0.151 | 0.028 | 0.151 | Potassium channel (Ca-activated) activator | 0.101 0.055 DBMET02215 | ||
| 0.136 | 0.013 | 0.146 | Carbamoyl phosphate synthetase inhibitor | 0.146 0.012 DBMET02215 | DBMET02215 | |
| 0.126 | 0.005 | 0.126 | CC chemokine 5 receptor antagonist | |||
| 0.133 | 0.012 | 0.133 | Alcohol oxidase inhibitor | 0.092 0.02 DBMET02215 | ||
| 0.133 | 0.012 | 0.154 | Sphingosine 1-phosphate receptor 4 agonist | 0.154 0.008 DBMET02215 | DBMET02215 | |
| 0.159 | 0.039 | 0.159 | Adenylate cyclase inhibitor | 0.133 0.057 DBMET02215 | ||
| 0.124 | 0.005 | 0.13 | Glutamate (mGluR6) antagonist | 0.13 0.005 DBMET02215 | DBMET02215 | |
| 0.225 | 0.107 | 0.259 | Immunostimulant | 0.259 0.093 DBMET02215 | DBMET02215 | |
| 0.129 | 0.011 | 0.129 | GABA receptor antagonist | |||
| 0.15 | 0.032 | 0.15 | Chemokine receptor antagonist | |||
| 0.161 | 0.044 | 0.161 | Sphingosine 1-phosphate receptor 5 antagonist | 0.14 0.08 DBMET02215 | ||
| 0.158 | 0.041 | 0.24 | Cholesterol synthesis inhibitor | 0.24 0.019 DBMET02215 | DBMET02215 | |
| 0.143 | 0.027 | 0.158 | Creatine kinase inhibitor | 0.158 0.021 DBMET02215 | DBMET02215 | |
| 0.142 | 0.026 | 0.154 | DOPA decarboxylase inhibitor | 0.154 0.019 DBMET02215 | DBMET02215 | |
| 0.123 | 0.008 | 0.134 | NMDA receptor glycine site agonist | 0.134 0.005 DBMET02215 | DBMET02215 | |
| 0.135 | 0.021 | 0.208 | Phosphofructokinase-1 inhibitor | 0.208 0.01 DBMET02215 | DBMET02215 | |
| 0.163 | 0.05 | 0.163 | Bone formation stimulant | 0.11 0.095 DBMET02215 | ||
| 0.133 | 0.02 | 0.133 | Glutamate (mGluR7) agonist | 0.097 0.065 DBMET02215 | ||
| 0.146 | 0.034 | 0.218 | TRPA1 agonist | 0.218 0.008 DBMET02215 | DBMET02215 | |
| 0.153 | 0.04 | 0.157 | Heat shock protein 70 antagonist | 0.157 0.032 DBMET02215 | DBMET02215 | |
| 0.122 | 0.01 | 0.122 | NMDA 2C receptor antagonist | 0.07 0.033 DBMET02215 | ||
| 0.314 | 0.203 | 0.314 | Antiinflammatory | |||
| 0.125 | 0.014 | 0.125 | GP IIb/IIIa receptor antagonist | |||
| 0.133 | 0.023 | 0.157 | NADH dehydrogenase inhibitor | 0.157 0.016 DBMET02215 | DBMET02215 | |
| 0.129 | 0.02 | 0.129 | Ornithine decarboxylase inhibitor | 0.111 0.033 DBMET02215 | ||
| 0.213 | 0.104 | 0.25 | DNA synthesis inhibitor | 0.25 0.066 DBMET02215 | DBMET02215 | |
| 0.253 | 0.145 | 0.253 | Immunosuppressant | 0.229 0.167 DBMET02215 | ||
| 0.111 | 0.005 | 0.111 | Glutamate (mGluR4) antagonist | 0.078 0.008 DBMET02215 | ||
| 0.119 | 0.015 | 0.119 | Argininosuccinate synthase inhibitor | 0.1 0.019 DBMET02215 | ||
| 0.112 | 0.009 | 0.121 | NMDA receptor subunit 3B antagonist | 0.121 0.009 DBMET02215 | DBMET02215 | |
| 0.124 | 0.023 | 0.124 | Inducible nitric-oxide synthase inhibitor | |||
| 0.139 | 0.039 | 0.139 | Mucolytic | 0.138 0.04 DBMET02215 | ||
| 0.253 | 0.154 | 0.253 | Antiobesity | |||
| 0.104 | 0.005 | 0.104 | AMPA 4 receptor antagonist | 0.06 0.01 DBMET02215 | ||
| 0.185 | 0.086 | 0.185 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.151 0.146 DBMET02215 | ||
| 0.114 | 0.015 | 0.212 | Biliverdin reductase inhibitor | 0.212 0.005 DBMET02215 | DBMET02215 | |
| 0.151 | 0.052 | 0.155 | Toll-Like receptor 2 antagonist | 0.155 0.049 DBMET02215 | DBMET02215 | |
| 0.102 | 0.004 | 0.102 | Lysine carboxypeptidase inhibitor | 0.029 0.017 DBMET02215 | ||
| 0.174 | 0.077 | 0.174 | Lipocortins synthesis antagonist | 0.142 0.117 DBMET02215 | ||
| 0.105 | 0.01 | 0.105 | Prostaglandin F2 alpha antagonist | 0.082 0.021 DBMET02215 | ||
| 0.1 | 0.005 | 0.1 | Integrin alpha5beta1 antagonist | |||
| 0.139 | 0.044 | 0.144 | Sphingosine 1-phosphate receptor 4 antagonist | 0.144 0.039 DBMET02215 | DBMET02215 | |
| 0.104 | 0.01 | 0.104 | Thromboxane antagonist | 0.083 0.019 DBMET02215 | ||
| 0.166 | 0.072 | 0.191 | Catenin beta inhibitor | 0.191 0.039 DBMET02215 | DBMET02215 | |
| 0.1 | 0.007 | 0.112 | MDM2 inhibitor | 0.112 0.005 DBMET02215 | DBMET02215 | |
| 0.126 | 0.034 | 0.126 | Prolactin inhibitor | 0.093 0.062 DBMET02215 | ||
| 0.122 | 0.033 | 0.122 | Protein kinase A inhibitor | |||
| 0.152 | 0.063 | 0.209 | Amylase inhibitor | 0.209 0.041 DBMET02215 | DBMET02215 | |
| 0.114 | 0.026 | 0.233 | Glutathione S-transferase inhibitor | 0.233 0.004 DBMET02215 | DBMET02215 | |
| 0.131 | 0.043 | 0.131 | Nav1.4 sodium channel blocker | |||
| 0.132 | 0.044 | 0.153 | Photosensitizer | 0.153 0.029 DBMET02215 | DBMET02215 | |
| 0.165 | 0.078 | 0.172 | ATPase inhibitor | 0.172 0.068 DBMET02215 | DBMET02215 | |
| 0.141 | 0.054 | 0.141 | Cathepsin H inhibitor | 0.119 0.076 DBMET02215 | ||
| 0.182 | 0.096 | 0.203 | Neurotrophic factor enhancer | 0.203 0.073 DBMET02215 | DBMET02215 | |
| 0.093 | 0.008 | 0.093 | Thromboxane synthase inhibitor | 0.081 0.011 DBMET02215 | ||
| 0.12 | 0.035 | 0.12 | Alcohol dehydrogenase inhibitor | 0.106 0.046 DBMET02215 | ||
| 0.112 | 0.028 | 0.112 | Bile acid receptor antagonist | 0.109 0.033 DBMET02215 | ||
| 0.096 | 0.017 | 0.096 | Ornithine carbamoyltransferase inhibitor | 0.08 0.021 DBMET02215 | ||
| 0.089 | 0.011 | 0.089 | Thromboxane A2 antagonist | 0.076 0.017 DBMET02215 | ||
| 0.082 | 0.005 | 0.082 | Glucagon receptor antagonist | 0.056 0.009 DBMET02215 | ||
| 0.108 | 0.03 | 0.108 | Cathepsin G inhibitor | 0.082 0.042 DBMET02215 | ||
| 0.107 | 0.031 | 0.107 | CC chemokine receptor antagonist | |||
| 0.081 | 0.005 | 0.081 | Dopamine beta hydroxylase inhibitor | 0.06 0.015 DBMET02215 | ||
| 0.081 | 0.005 | 0.081 | Integrin beta3 antagonist | |||
| 0.086 | 0.01 | 0.109 | NMDA receptor subunit 3A antagonist | 0.109 0.008 DBMET02215 | DBMET02215 | |
| 0.139 | 0.065 | 0.139 | Nav1.2 sodium channel blocker | |||
| 0.077 | 0.004 | 0.077 | Integrin alphaVbeta1 antagonist | |||
| 0.082 | 0.009 | 0.243 | Kainate receptor antagonist | 0.243 0.004 DBMET02215 | DBMET02215 | |
| 0.08 | 0.007 | 0.08 | Glutamate (mGluR group III) antagonist | 0.06 0.013 DBMET02215 | ||
| 0.11 | 0.037 | 0.11 | Histamine N-methyltransferase inhibitor | |||
| 0.099 | 0.026 | 0.099 | Estrogen-related receptor beta agonist | 0.095 0.032 DBMET02215 | ||
| 0.087 | 0.015 | 0.087 | Glycine transporter 2 inhibitor | |||
| 0.117 | 0.046 | 0.117 | Carbonic anhydrase III inhibitor | 0.099 0.063 DBMET02215 | ||
| 0.149 | 0.079 | 0.192 | Interferon gamma antagonist | 0.192 0.044 DBMET02215 | DBMET02215 | |
| 0.104 | 0.034 | 0.104 | Glutamate receptor agonist | |||
| 0.147 | 0.079 | 0.164 | Diuretic | 0.164 0.066 DBMET02215 | DBMET02215 | |
| 0.087 | 0.021 | 0.105 | Prostaglandin antagonist | 0.105 0.016 DBMET02215 | DBMET02215 | |
| 0.081 | 0.016 | 0.081 | Neurokinin antagonist | |||
| 0.098 | 0.034 | 0.145 | Glycine receptor antagonist | 0.145 0.009 DBMET02215 | DBMET02215 | |
| 0.186 | 0.122 | 0.204 | RNA-directed DNA polymerase inhibitor | 0.204 0.094 DBMET02215 | DBMET02215 | |
| 0.072 | 0.008 | 0.08 | Fumarate hydratase inhibitor | 0.08 0.007 DBMET02215 | DBMET02215 | |
| 0.066 | 0.005 | 0.097 | Kainate receptor agonist | 0.097 0.003 DBMET02215 | DBMET02215 | |
| 0.079 | 0.018 | 0.079 | Botulinum neurotoxin type A inhibitor | 0.067 0.028 DBMET02215 | ||
| 0.088 | 0.028 | 0.126 | Vanilloid 4 agonist | 0.126 0.005 DBMET02215 | DBMET02215 | |
| 0.166 | 0.106 | 0.166 | Interleukin antagonist | |||
| 0.108 | 0.049 | 0.108 | Nitric-oxide synthase inhibitor | |||
| 0.085 | 0.027 | 0.106 | Phospholipase D inhibitor | 0.106 0.011 DBMET02215 | DBMET02215 | |
| 0.064 | 0.006 | 0.068 | Glutamate (mGluR8) agonist | 0.068 0.005 DBMET02215 | DBMET02215 | |
| 0.066 | 0.009 | 0.066 | Arginase inhibitor | 0.04 0.022 DBMET02215 | ||
| 0.115 | 0.059 | 0.115 | Chelator | |||
| 0.076 | 0.021 | 0.076 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.103 | 0.047 | 0.103 | Protein kinase C zeta inhibitor | |||
| 0.059 | 0.005 | 0.071 | Kynurenine 3 monooxygenase inhibitor | 0.071 0.004 DBMET02215 | DBMET02215 | |
| 0.063 | 0.01 | 0.221 | Kainate receptor 2 antagonist | 0.221 0.003 DBMET02215 | DBMET02215 | |
| 0.164 | 0.112 | 0.164 | Platelet aggregation inhibitor | |||
| 0.097 | 0.048 | 0.097 | Aminoacyl-tRNA synthetase inhibitor | |||
| 0.059 | 0.01 | 0.059 | Factor VII inhibitor | |||
| 0.055 | 0.007 | 0.055 | Free fatty acid receptor 1 antagonist | 0.043 0.013 DBMET02215 | ||
| 0.091 | 0.043 | 0.098 | D-Ala-D-Ala ligase inhibitor | 0.098 0.032 DBMET02215 | DBMET02215 | |
| 0.068 | 0.02 | 0.068 | Bombesin 2 receptor antagonist | |||
| 0.108 | 0.06 | 0.117 | Expectorant | 0.117 0.053 DBMET02215 | DBMET02215 | |
| 0.048 | 0.002 | 0.048 | Integrin beta6 antagonist | 0.016 0.007 DBMET02215 | ||
| 0.065 | 0.019 | 0.065 | Complement C3a chemotactic receptor antagonist | |||
| 0.049 | 0.004 | 0.049 | Prostaglandin H2 antagonist | 0.038 0.007 DBMET02215 | ||
| 0.065 | 0.02 | 0.065 | Sphingosine 1-phosphate receptor 5 agonist | 0.063 0.022 DBMET02215 | ||
| 0.052 | 0.007 | 0.093 | ATP citrate lysase inhibitor | 0.093 0.004 DBMET02215 | DBMET02215 | |
| 0.071 | 0.026 | 0.101 | Acyl-CoA dehydrogenase inhibitor | 0.101 0.016 DBMET02215 | DBMET02215 | |
| 0.128 | 0.083 | 0.128 | Histone deacetylase SIRT1 inhibitor | |||
| 0.134 | 0.09 | 0.162 | Pregnane X receptor agonist | 0.162 0.035 DBMET02215 | DBMET02215 | |
| 0.059 | 0.015 | 0.059 | AICAR transformylase inhibitor | 0.043 0.033 DBMET02215 | ||
| 0.057 | 0.013 | 0.057 | Dopamine D5 agonist | |||
| 0.051 | 0.008 | 0.051 | Glutamate (mGluR8) antagonist | 0.046 0.011 DBMET02215 | ||
| 0.072 | 0.03 | 0.072 | Caspase 9 inhibitor | 0.067 0.035 DBMET02215 | ||
| 0.055 | 0.013 | 0.08 | Retinoid X alpha receptor agonist | 0.08 0.007 DBMET02215 | DBMET02215 | |
| 0.047 | 0.005 | 0.047 | Thyroid hormone agonist | 0.026 0.019 DBMET02215 | ||
| 0.05 | 0.009 | 0.05 | AMPA 3 receptor antagonist | 0.04 0.014 DBMET02215 | ||
| 0.104 | 0.063 | 0.104 | Urease inhibitor | |||
| 0.055 | 0.014 | 0.055 | Dihydrofolate reductase inhibitor | 0.042 0.035 DBMET02215 | ||
| 0.103 | 0.063 | 0.103 | Carbonic anhydrase XV inhibitor | |||
| 0.046 | 0.007 | 0.046 | Tryptophan 5 hydroxylase inhibitor | 0.04 0.014 DBMET02215 | ||
| 0.046 | 0.008 | 0.046 | Carboxypeptidase B inhibitor | |||
| 0.112 | 0.075 | 0.112 | DNA polymerase I inhibitor | |||
| 0.065 | 0.028 | 0.065 | GABA A receptor antagonist | |||
| 0.05 | 0.014 | 0.058 | p53 inhibitor | 0.058 0.01 DBMET02215 | DBMET02215 | |
| 0.075 | 0.039 | 0.075 | Potassium channel large-conductance Ca-activated activator | 0.062 0.056 DBMET02215 | ||
| 0.14 | 0.105 | 0.171 | Interleukin 6 antagonist | 0.171 0.063 DBMET02215 | DBMET02215 | |
| 0.069 | 0.034 | 0.091 | Prostaglandin EP2 antagonist | 0.091 0.022 DBMET02215 | DBMET02215 | |
| 0.068 | 0.033 | 0.068 | Carbonic anhydrase stimulant | |||
| 0.101 | 0.066 | 0.101 | Factor V inhibitor | |||
| 0.043 | 0.008 | 0.043 | Glutamate (mGluR3) agonist | 0.04 0.01 DBMET02215 | ||
| 0.099 | 0.064 | 0.165 | Anabolic | 0.165 0.011 DBMET02215 | DBMET02215 | |
| 0.056 | 0.022 | 0.083 | Glucose-6-phosphate isomerase inhibitor | 0.083 0.008 DBMET02215 | DBMET02215 | |
| 0.041 | 0.007 | 0.188 | Kainate receptor 1 antagonist | 0.188 0.003 DBMET02215 | DBMET02215 | |
| 0.078 | 0.044 | 0.078 | NMDA 2 receptor antagonist | |||
| 0.049 | 0.016 | 0.054 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.054 0.011 DBMET02215 | DBMET02215 | |
| 0.143 | 0.109 | 0.143 | Amyloid beta precursor protein antagonist | |||
| 0.104 | 0.071 | 0.104 | 5 Hydroxytryptamine 3A agonist | |||
| 0.045 | 0.012 | 0.045 | AMPA receptor agonist | |||
| 0.136 | 0.103 | 0.187 | Melanin inhibitor | 0.187 0.047 DBMET02215 | DBMET02215 | |
| 0.049 | 0.017 | 0.049 | Membrane dipeptidase inhibitor | 0.048 0.018 DBMET02215 | ||
| 0.071 | 0.04 | 0.136 | Exportin-1 inhibitor | 0.136 0.004 DBMET02215 | DBMET02215 | |
| 0.095 | 0.064 | 0.105 | Interleukin 1 beta converting enzyme inhibitor | 0.105 0.051 DBMET02215 | DBMET02215 | |
| 0.066 | 0.036 | 0.072 | Calcium channel P-type blocker | 0.072 0.025 DBMET02215 | DBMET02215 | |
| 0.059 | 0.029 | 0.06 | DNA helicase inhibitor | 0.06 0.028 DBMET02215 | DBMET02215 | |
| 0.046 | 0.016 | 0.046 | Phosphoglycerate kinase inhibitor | 0.035 0.024 DBMET02215 | ||
| 0.056 | 0.027 | 0.056 | Glycine transporter inhibitor | |||
| 0.052 | 0.023 | 0.052 | Glutamate (mGluR group III) agonist | 0.039 0.036 DBMET02215 | ||
| 0.047 | 0.018 | 0.066 | GABA uptake inhibitor | 0.066 0.008 DBMET02215 | DBMET02215 | |
| 0.046 | 0.017 | 0.046 | Glucagon-like peptide 1 receptor antagonist | 0.038 0.032 DBMET02215 | ||
| 0.08 | 0.051 | 0.081 | Na+ K+ transporting ATPase inhibitor | 0.081 0.049 DBMET02215 | DBMET02215 | |
| 0.041 | 0.013 | 0.041 | Integrin alpha4 antagonist | |||
| 0.049 | 0.021 | 0.049 | Sphingosine 1-phosphate receptor 1 agonist | |||
| 0.048 | 0.021 | 0.048 | Histamine H1 receptor agonist | |||
| 0.05 | 0.022 | 0.05 | Histamine H2 receptor agonist | |||
| 0.043 | 0.015 | 0.051 | Integrin alpha1beta1 antagonist | 0.051 0.007 DBMET02215 | DBMET02215 | |
| 0.05 | 0.024 | 0.05 | Macrophage elastase inhibitor | |||
| 0.035 | 0.01 | 0.035 | LFA antagonist | 0.027 0.021 DBMET02215 | ||
| 0.06 | 0.036 | 0.06 | Potassium channel Kv1.5 blocker | |||
| 0.122 | 0.097 | 0.144 | Mannose-6-phosphate isomerase inhibitor | 0.144 0.07 DBMET02215 | DBMET02215 | |
| 0.043 | 0.02 | 0.043 | Kinesin antagonist | |||
| 0.043 | 0.02 | 0.043 | Kinesin-like protein 1 inhibitor | |||
| 0.049 | 0.026 | 0.049 | Sphingosine 1-phosphate receptor agonist | |||
| 0.05 | 0.027 | 0.05 | CC chemokine 4 receptor antagonist | |||
| 0.097 | 0.074 | 0.117 | Toll-Like receptor 4 antagonist | 0.117 0.047 DBMET02215 | DBMET02215 | |
| 0.038 | 0.015 | 0.038 | Dipeptidyl peptidase II inhibitor | |||
| 0.048 | 0.025 | 0.048 | Parathyroid hormone antagonist | |||
| 0.044 | 0.022 | 0.044 | Substance P antagonist | |||
| 0.074 | 0.051 | 0.074 | Rho-associated kinase II inhibitor | |||
| 0.037 | 0.016 | 0.037 | AMPA 1 receptor antagonist | 0.025 0.023 DBMET02215 | ||
| 0.076 | 0.055 | 0.076 | Sphingosine 1-phosphate receptor antagonist | 0.075 0.056 DBMET02215 | ||
| 0.057 | 0.036 | 0.057 | Sphingosine 1-phosphate receptor 1 antagonist | 0.053 0.046 DBMET02215 | ||
| 0.039 | 0.018 | 0.045 | Peroxisome proliferator-activated receptor delta agonist | 0.045 0.014 DBMET02215 | DBMET02215 | |
| 0.042 | 0.021 | 0.087 | Retinoid X receptor agonist | 0.087 0.006 DBMET02215 | DBMET02215 | |
| 0.029 | 0.009 | 0.041 | Prostaglandin F2 alpha agonist | 0.041 0.005 DBMET02215 | DBMET02215 | |
| 0.036 | 0.016 | 0.036 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.051 | 0.033 | 0.056 | CD45 antagonist | 0.056 0.025 DBMET02215 | DBMET02215 | |
| 0.166 | 0.148 | 0.166 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.035 | 0.017 | 0.035 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.022 | 0.005 | 0.029 | Thromboxane A2 agonist | 0.029 0.003 DBMET02215 | DBMET02215 | |
| 0.041 | 0.024 | 0.044 | VCAM-1 antagonist | 0.044 0.015 DBMET02215 | DBMET02215 | |
| 0.04 | 0.024 | 0.044 | VCAM antagonist | 0.044 0.015 DBMET02215 | DBMET02215 | |
| 0.055 | 0.038 | 0.055 | Epithelial sodium channel blocker | |||
| 0.127 | 0.111 | 0.205 | GABA C receptor rho-2 antagonist | 0.205 0.026 DBMET02215 | DBMET02215 | |
| 0.021 | 0.005 | 0.021 | Integrin alphaVbeta6 antagonist | |||
| 0.077 | 0.061 | 0.077 | Carbonic anhydrase VI inhibitor | |||
| 0.044 | 0.029 | 0.044 | Carbonic anhydrase IV inhibitor | |||
| 0.102 | 0.088 | 0.115 | Caspase 3 inhibitor | 0.115 0.068 DBMET02215 | DBMET02215 | |
| 0.041 | 0.027 | 0.041 | Neurokinin 1 antagonist | |||
| 0.025 | 0.011 | 0.025 | ICAM 1 antagonist | |||
| 0.023 | 0.009 | 0.033 | Retinoid X beta receptor antagonist | 0.033 0.004 DBMET02215 | DBMET02215 | |
| 0.069 | 0.055 | 0.071 | Peroxisome proliferator-activated receptor gamma antagonist | 0.071 0.052 DBMET02215 | DBMET02215 | |
| 0.081 | 0.067 | 0.201 | Vanilloid agonist | 0.201 0.007 DBMET02215 | DBMET02215 | |
| 0.025 | 0.012 | 0.025 | Glutamate (mGluR1a) agonist | 0.022 0.016 DBMET02215 | ||
| 0.037 | 0.025 | 0.056 | Integrin alpha2 antagonist | 0.056 0.009 DBMET02215 | DBMET02215 | |
| 0.014 | 0.002 | 0.014 | Integrin alpha5beta6 antagonist | |||
| 0.034 | 0.024 | 0.034 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | |||
| 0.019 | 0.009 | 0.019 | CXC chemokine 5 receptor antagonist | |||
| 0.087 | 0.077 | 0.087 | Sphingomyelinase inhibitor | |||
| 0.044 | 0.034 | 0.044 | Mannosidase inhibitor | |||
| 0.04 | 0.032 | 0.04 | Oxytocin agonist | |||
| 0.027 | 0.018 | 0.027 | VLA-4 antagonist | |||
| 0.085 | 0.076 | 0.103 | ABCA1 expression enhancer | 0.103 0.046 DBMET02215 | DBMET02215 | |
| 0.027 | 0.019 | 0.033 | Retinoid X gamma receptor antagonist | 0.033 0.008 DBMET02215 | DBMET02215 | |
| 0.014 | 0.006 | 0.014 | Glutamate (mGluR6) agonist | 0.013 0.007 DBMET02215 | ||
| 0.013 | 0.005 | 0.016 | Thromboxane agonist | 0.016 0.004 DBMET02215 | DBMET02215 | |
| 0.012 | 0.004 | 0.012 | Thyroid hormone beta agonist | |||
| 0.023 | 0.015 | 0.023 | Isoleucine-tRNA ligase inhibitor | |||
| 0.017 | 0.011 | 0.017 | Carbonic anhydrase VIII inhibitor | 0.016 0.012 DBMET02215 | ||
| 0.017 | 0.011 | 0.017 | Carbonic anhydrase X inhibitor | 0.016 0.012 DBMET02215 | ||
| 0.01 | 0.004 | 0.01 | Free fatty acid receptor 2 antagonist | 0.008 0.007 DBMET02215 | ||
| 0.054 | 0.048 | 0.08 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.08 0.024 DBMET02215 | DBMET02215 | |
| 0.121 | 0.116 | 0.121 | Thiol protease inhibitor | |||
| 0.058 | 0.053 | 0.058 | Nitric oxide donor | |||
| 0.052 | 0.048 | 0.055 | Adenine nucleotide translocase inhibitor | 0.055 0.039 DBMET02215 | DBMET02215 | |
| 0.129 | 0.124 | 0.129 | Antipruritic | |||
| 0.018 | 0.013 | 0.018 | Complement factor D inhibitor | |||
| 0.017 | 0.012 | 0.027 | G-protein-coupled receptor 120 agonist | 0.027 0.006 DBMET02215 | DBMET02215 | |
| 0.037 | 0.032 | 0.037 | Erythropoietin receptor agonist | |||
| 0.025 | 0.021 | 0.025 | Urotensin II agonist | |||
| 0.016 | 0.012 | 0.016 | Thyroid hormone alpha agonist | |||
| 0.01 | 0.007 | 0.01 | Integrin alphaVbeta5 antagonist | |||
| 0.071 | 0.068 | 0.071 | Histamine H1 receptor antagonist | |||
| 0.011 | 0.008 | 0.011 | Carboxypeptidase B2 inhibitor | |||
| 0.185 | 0.182 | 0.185 | Immunomodulator | |||
| 0.215 | 0.213 | 0.215 | Antibacterial | |||
| 0.057 | 0.056 | 0.057 | Trypsin inhibitor | |||
| 0.035 | 0.033 | 0.052 | Retinoid X receptor antagonist | 0.052 0.011 DBMET02215 | DBMET02215 | |
| 0.014 | 0.012 | 0.014 | Integrin alpha4beta1 antagonist | |||
| 0.048 | 0.047 | 0.048 | Alpha-mannosidase inhibitor | |||
| 0.033 | 0.032 | 0.042 | Diamine oxidase inhibitor | 0.042 0.021 DBMET02215 | DBMET02215 | |
| 0.079 | 0.077 | 0.079 | Hematopoietic | |||
| 0.046 | 0.045 | 0.046 | Ribonucleotide reductase inhibitor | |||
| 0.027 | 0.026 | 0.037 | Prostaglandin D2 agonist | 0.037 0.015 DBMET02215 | DBMET02215 | |
| 0.024 | 0.023 | 0.024 | Calcium-sensing receptor agonist | |||
| 0.039 | 0.038 | 0.039 | Neurotensin receptor antagonist | |||
| 0.023 | 0.022 | 0.033 | Glutamate (mGluR1) agonist | 0.033 0.008 DBMET02215 | DBMET02215 | |
| 0.017 | 0.017 | 0.018 | Methylmalonyl-CoA mutase inhibitor | 0.018 0.012 DBMET02215 | DBMET02215 | |
| 0.03 | 0.033 | 0.044 | Retinoid X alpha receptor antagonist | 0.044 0.01 DBMET02215 | DBMET02215 | |
| 0.04 | 0.043 | 0.054 | Heme oxygenase inhibitor | 0.054 0.009 DBMET02215 | DBMET02215 | |
| 0.067 | 0.071 | 0.081 | Keratolytic | 0.081 0.047 DBMET02215 | DBMET02215 | |
| 0.067 | 0.072 | 0.073 | Macrophage migration inhibitory factor inhibitor | 0.073 0.061 DBMET02215 | DBMET02215 | |
| 0.039 | 0.044 | 0.051 | Thymidylate synthase inhibitor | 0.051 0.026 DBMET02215 | DBMET02215 | |
| 0.03 | 0.034 | 0.031 | Glutamate (mGluR4) agonist | 0.031 0.03 DBMET02215 | DBMET02215 | |
| 0.052 | 0.057 | 0.076 | Pregnane X receptor antagonist | 0.076 0.009 DBMET02215 | DBMET02215 | |
| 0.052 | 0.058 | 0.079 | Purinergic P2X1 antagonist | 0.079 0.025 DBMET02215 | DBMET02215 | |
| 0.023 | 0.028 | 0.028 | Liver X receptor beta antagonist | 0.028 0.021 DBMET02215 | DBMET02215 | |
| 0.051 | 0.06 | 0.07 | Leukotriene C antagonist | 0.07 0.014 DBMET02215 | DBMET02215 | |
| 0.034 | 0.044 | 0.06 | Phosphorylase inhibitor | 0.06 0.025 DBMET02215 | DBMET02215 | |
| 0.022 | 0.031 | 0.033 | Integrin alpha2beta1 antagonist | 0.033 0.01 DBMET02215 | DBMET02215 | |
| 0.019 | 0.031 | 0.035 | Uridine phosphorylase inhibitor | 0.035 0.014 DBMET02215 | DBMET02215 | |
| 0.017 | 0.029 | 0.033 | NMDA receptor glycine site antagonist | 0.033 0.011 DBMET02215 | DBMET02215 | |
| 0.023 | 0.036 | 0.04 | Prostaglandin agonist | 0.04 0.014 DBMET02215 | DBMET02215 | |
| 0.039 | 0.053 | 0.049 | Carnitine palmitoyltransferase 1B inhibitor | 0.049 0.03 DBMET02215 | DBMET02215 | |
| 0.051 | 0.065 | 0.086 | Leukotriene antagonist | 0.086 0.028 DBMET02215 | DBMET02215 | |
| 0.125 | 0.141 | 0.148 | Hepatoprotectant | 0.148 0.112 DBMET02215 | DBMET02215 | |
| 0.013 | 0.03 | 0.025 | Prostaglandin EP2 agonist | 0.025 0.015 DBMET02215 | DBMET02215 | |
| 0.012 | 0.03 | 0.02 | Kainate receptor 5 antagonist | 0.02 0.015 DBMET02215 | DBMET02215 | |
| 0.029 | 0.047 | 0.037 | Dihydropteroate synthase inhibitor | 0.037 0.032 DBMET02215 | DBMET02215 | |
| 0.054 | 0.073 | 0.071 | Prostaglandin-E synthase inhibitor | 0.071 0.047 DBMET02215 | DBMET02215 | |
| 0.02 | 0.038 | 0.031 | Vanilloid 2 agonist | 0.031 0.009 DBMET02215 | DBMET02215 | |
| 0.05 | 0.069 | 0.093 | Peroxisome proliferator-activated receptor gamma agonist | 0.093 0.032 DBMET02215 | DBMET02215 | |
| 0.035 | 0.055 | 0.059 | Adenylate cyclase 1 inhibitor | 0.059 0.019 DBMET02215 | DBMET02215 | |
| 0.014 | 0.034 | 0.029 | Prostaglandin E2 agonist | 0.029 0.011 DBMET02215 | DBMET02215 | |
| 0.006 | 0.027 | 0.033 | Prostaglandin EP4 agonist | 0.033 0.007 DBMET02215 | DBMET02215 | |
| 0.026 | 0.046 | 0.031 | Peroxisome proliferator-activated receptor delta antagonist | 0.031 0.029 DBMET02215 | DBMET02215 | |
| 0.059 | 0.079 | 0.091 | CYP2A6 inhibitor | 0.091 0.041 DBMET02215 | DBMET02215 | |
| 0.042 | 0.064 | 0.06 | Leukotriene B4 antagonist | 0.06 0.028 DBMET02215 | DBMET02215 | |
| 0.033 | 0.056 | 0.048 | Leukotriene C4 antagonist | 0.048 0.012 DBMET02215 | DBMET02215 | |
| 0.106 | 0.132 | 0.156 | Protein-tyrosine phosphatase inhibitor | 0.156 0.073 DBMET02215 | DBMET02215 | |
| 0.122 | 0.149 | 0.137 | DNA methylase inhibitor | 0.137 0.129 DBMET02215 | DBMET02215 | |
| 0.008 | 0.036 | 0.06 | Prostacyclin agonist | 0.06 0.004 DBMET02215 | DBMET02215 | |
| 0.03 | 0.059 | 0.05 | Peroxisome proliferator-activated receptor alpha agonist | 0.05 0.032 DBMET02215 | DBMET02215 | |
| 0.043 | 0.074 | 0.068 | Dihydroorotate oxidase inhibitor | 0.068 0.019 DBMET02215 | DBMET02215 | |
| 0.056 | 0.089 | 0.096 | CDC25A inhibitor | 0.096 0.03 DBMET02215 | DBMET02215 | |
| 0.159 | 0.192 | 0.262 | Lipoxygenase inhibitor | 0.262 0.092 DBMET02215 | DBMET02215 | |
| 0.072 | 0.106 | 0.093 | Thioredoxin inhibitor | 0.093 0.057 DBMET02215 | DBMET02215 | |
| 0.106 | 0.142 | 0.175 | Hexokinase inhibitor | 0.175 0.053 DBMET02215 | DBMET02215 | |
| 0.031 | 0.067 | 0.04 | Nerve growth factor antagonist | 0.04 0.035 DBMET02215 | DBMET02215 | |
| 0.032 | 0.069 | 0.062 | Prostaglandin E2 antagonist | 0.062 0.028 DBMET02215 | DBMET02215 | |
| 0.034 | 0.072 | 0.063 | Lysophosphatidic acid 3 receptor antagonist | 0.063 0.019 DBMET02215 | DBMET02215 | |
| 0.007 | 0.048 | 0.015 | 5-Alpha-reductase 1 inhibitor | 0.015 0.013 DBMET02215 | DBMET02215 | |
| 0.039 | 0.081 | 0.049 | Heparanase inhibitor | 0.049 0.047 DBMET02215 | DBMET02215 | |
| 0.011 | 0.057 | 0.031 | Retinoid X gamma receptor agonist | 0.031 0.01 DBMET02215 | DBMET02215 | |
| 0.068 | 0.117 | 0.111 | UDP-glucose 4-epimerase inhibitor | 0.111 0.05 DBMET02215 | DBMET02215 | |
| 0.01 | 0.06 | 0.031 | Retinoid X beta receptor agonist | 0.031 0.008 DBMET02215 | DBMET02215 | |
| 0.016 | 0.067 | 0.072 | 5-Alpha-reductase inhibitor | 0.072 0.014 DBMET02215 | DBMET02215 | |
| 0.01 | 0.063 | 0.038 | Squalene synthetase inhibitor | 0.038 0.019 DBMET02215 | DBMET02215 | |
| 0.118 | 0.172 | 0.159 | 3C-like protease (Human coronavirus) inhibitor | 0.159 0.087 DBMET02215 | DBMET02215 | |
| 0.014 | 0.069 | 0.026 | Nicotinic acid receptor 2 antagonist | 0.026 0.019 DBMET02215 | DBMET02215 | |
| 0.029 | 0.085 | 0.088 | Plasminogen activator inhibitor antagonist | 0.088 0.013 DBMET02215 | DBMET02215 | |
| 0.035 | 0.091 | 0.068 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.068 0.027 DBMET02215 | DBMET02215 | |
| 0.025 | 0.081 | 0.032 | HCV polyprotein inhibitor | 0.032 0.03 DBMET02215 | DBMET02215 | |
| 0.017 | 0.074 | 0.035 | Lysophosphatidic acid 2 receptor antagonist | 0.035 0.016 DBMET02215 | DBMET02215 | |
| 0.076 | 0.136 | 0.139 | Glutamate receptor antagonist | 0.139 0.059 DBMET02215 | DBMET02215 | |
| 0.01 | 0.074 | 0.021 | Leukotriene B4 receptor 2 antagonist | 0.021 0.016 DBMET02215 | DBMET02215 | |
| 0.063 | 0.13 | 0.111 | Protein-tyrosine phosphatase 1B inhibitor | 0.111 0.069 DBMET02215 | DBMET02215 | |
| 0.01 | 0.079 | 0.035 | Leukotriene B4 receptor 1 antagonist | 0.035 0.015 DBMET02215 | DBMET02215 | |
| 0.102 | 0.176 | 0.145 | DNA methyltransferase I inhibitor | 0.145 0.109 DBMET02215 | DBMET02215 | |
| 0.155 | 0.234 | 0.209 | Vasodilator, peripheral | 0.209 0.165 DBMET02215 | DBMET02215 | |
| 0.235 | 0.314 | 0.267 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.267 0.261 DBMET02215 | DBMET02215 | |
| 0.053 | 0.135 | 0.179 | 5-Lipoxygenase inhibitor | 0.179 0.029 DBMET02215 | DBMET02215 | |
| 0.026 | 0.111 | 0.037 | Vanilloid 3 antagonist | 0.037 0.031 DBMET02215 | DBMET02215 | |
| 0.012 | 0.099 | 0.025 | Retinoic acid gamma receptor agonist | 0.025 0.01 DBMET02215 | DBMET02215 | |
| 0.073 | 0.175 | 0.138 | NADPH oxidase inhibitor | 0.138 0.063 DBMET02215 | DBMET02215 | |
| 0.066 | 0.169 | 0.102 | Microtubule formation inhibitor | 0.102 0.087 DBMET02215 | DBMET02215 | |
| 0.051 | 0.16 | 0.075 | Estrogen receptor alpha antagonist | 0.075 0.057 DBMET02215 | DBMET02215 | |
| 0.019 | 0.13 | 0.053 | Retinoic acid alpha receptor agonist | 0.053 0.012 DBMET02215 | DBMET02215 | |
| 0.057 | 0.17 | 0.097 | Transcription factor NF kappa B stimulant | 0.097 0.042 DBMET02215 | DBMET02215 | |
| 0.046 | 0.16 | 0.086 | ErbB-3 antagonist | 0.086 0.054 DBMET02215 | DBMET02215 | |
| 0.023 | 0.138 | 0.053 | HIV-1 integrase (Strand Transfer) inhibitor | 0.053 0.047 DBMET02215 | DBMET02215 | |
| 0.111 | 0.229 | 0.166 | Antioxidant | 0.166 0.147 DBMET02215 | DBMET02215 | |
| 0.009 | 0.128 | 0.021 | Retinoic acid beta receptor agonist | 0.021 0.011 DBMET02215 | DBMET02215 | |
| 0.027 | 0.147 | 0.086 | Androgen agonist | 0.086 0.021 DBMET02215 | DBMET02215 | |
| 0.125 | 0.252 | 0.233 | 12-Lipoxygenase inhibitor | 0.233 0.12 DBMET02215 | DBMET02215 | |
| 0.025 | 0.155 | 0.044 | Aldosterone antagonist | 0.044 0.038 DBMET02215 | DBMET02215 | |
| 0.032 | 0.164 | 0.159 | Factor III inhibitor | 0.159 0.003 DBMET02215 | DBMET02215 | |
| 0.058 | 0.207 | 0.118 | Alkaline phosphatase inhibitor | 0.118 0.089 DBMET02215 | DBMET02215 | |
| 0.008 | 0.166 | 0.023 | Retinoic acid receptor agonist | 0.023 0.017 DBMET02215 | DBMET02215 | |
| 0.077 | 0.251 | 0.161 | Nitric oxide antagonist | 0.161 0.087 DBMET02215 | DBMET02215 | |
| 0.02 | 0.203 | 0.109 | MAO B inhibitor | 0.109 0.056 DBMET02215 | DBMET02215 | |
| 0.112 | 0.295 | 0.201 | Transcription factor STAT3 inhibitor | 0.201 0.132 DBMET02215 | DBMET02215 | |
| 0.01 | 0.203 | 0.039 | Inosine monophosphate dehydrogenase inhibitor | 0.039 0.023 DBMET02215 | DBMET02215 | |
| 0.032 | 0.226 | 0.1 | HIV-1 integrase inhibitor | 0.1 0.025 DBMET02215 | DBMET02215 | |
| 0.031 | 0.235 | 0.14 | MAO inhibitor | 0.14 0.065 DBMET02215 | DBMET02215 | |
| 0.059 | 0.264 | 0.137 | Pyruvate kinase inhibitor | 0.137 0.128 DBMET02215 | DBMET02215 | |
| 0.108 | 0.323 | 0.177 | Transcription factor STAT inhibitor | 0.177 0.172 DBMET02215 | DBMET02215 | |
| 0.013 | 0.242 | 0.056 | Estrogen-related receptor beta antagonist | 0.056 0.004 DBMET02215 | DBMET02215 | |
| 0.048 | 0.3 | 0.119 | Estrogen antagonist | 0.119 0.058 DBMET02215 | DBMET02215 | |
| 0.033 | 0.331 | 0.091 | Estrogen receptor beta antagonist | 0.091 0.081 DBMET02215 | DBMET02215 | |
| 0.093 | 0.454 | 0.24 | Caspase 3 stimulant | 0.24 0.121 DBMET02215 | DBMET02215 | |
| 0.038 | 0.449 | 0.08 | Ca(v)3.1 blocker | 0.08 0.06 DBMET02215 | DBMET02215 | |
| 0.063 | 0.59 | 0.575 | Apoptosis agonist | 0.575 0.055 DBMET02215 | DBMET02215 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |